Previous 10 | Next 10 |
Last week, I wrote "it's time to take a step back, breathe deep, and objectively identify money-making opportunities," and I reminded investors that "if you were in cash during the top 10 best days in the stock market over the past 20 years, then your overall return is half what it would've ...
There have been a few "generational" events that have impacted stocks since I began helping professional mutual fund and hedge fund portfolio managers in the late 1990s. Covid-19 is another one of these events. These moments are incredibly scary for investors, and more broadly, society. An...
Image source: The Motley Fool. ChemoCentryx Inc (NASDAQ: CCXI) Q4 2019 Earnings Call Mar 10, 2020 , 5:00 p.m. ET Operator Continue reading
ChemoCentryx, Inc. (CCXI) Q4 2019 Earnings Conference Call March 10, 2020, 05:00 PM ET Company Participants Bill Slattery - IR Thomas Schall - Founder, President, CEO and Chairman Susan Kanaya - EVP, Chief Financial & Administrative Officer and Secretary Conference Call Pa...
The following slide deck was published by ChemoCentryx, Inc. in conjunction with their 2019 Q4 earnings Read more ...
ChemoCentryx, Inc. (NASDAQ: CCXI ): Q4 GAAP EPS of -$0.26 in-line. More news on: ChemoCentryx, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
-- Announced positive topline data from pivotal Phase III ADVOCATE trial for ANCA-vasculitis in Q4; U.S. NDA filing expected mid-2020 -- -- “2020 4-Sight” on the horizon with topline data from four clinical trials expected in 2020: AURORA and ACCOLADE clinical tri...
The threat of declining earnings because of reduced economic activity caused by the spread of the coronavirus, Covid-19, has finally overtaken the unbridled optimism that's been fueled by seasonal tailwinds , a resolution of impeachment worries, and decreasing trade tensions. As a result, o...
Healthcare Pulse Source: Bloomberg The fear of Coronavirus (Covid-19) has infected the stock market. The market's patience completely ran out this week as the Coronavirus news, which has continued to weigh heavily on the negative side, sent the market reeling in a feral pullback. Wha...
MOUNTAIN VIEW, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 9th Annual SVB Leerink Healthcare Conference on Wednesday, February 26, 2020 at 3:00 p.m. ET....
News, Short Squeeze, Breakout and More Instantly...
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX PR Newswire TAVNEOS ® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif. , Oct. 20, ...
-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS ® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR -- SAN CARLOS, Calif., Oct. 17,...
-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model -- SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), tod...